These findings suggested that AP3B2, ITGA10, ITPK1, and PTCH1 may be markers of resistance to taxane-based neoadjuvant chemotherapy in ER+/HER2- breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.